These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 20400900)
1. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. Fuchs I; Spiel AO; Frossard M; Derhaschnig U; Riedmüller E; Jilma B Crit Care Med; 2010 Jun; 38(6):1423-9. PubMed ID: 20400900 [TBL] [Abstract][Full Text] [Related]
2. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. Acikel S; Yildirir A; Aydinalp A; Bal U; Kaynar G; Ozin B; Muderrisoglu H Blood Coagul Fibrinolysis; 2009 Sep; 20(6):427-32. PubMed ID: 19542882 [TBL] [Abstract][Full Text] [Related]
3. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169 [TBL] [Abstract][Full Text] [Related]
5. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015 [TBL] [Abstract][Full Text] [Related]
6. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889 [TBL] [Abstract][Full Text] [Related]
7. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Homoncik M; Jilma B; Hergovich N; Stohlawetz P; Panzer S; Speiser W Thromb Haemost; 2000 Feb; 83(2):316-21. PubMed ID: 10739392 [TBL] [Abstract][Full Text] [Related]
8. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184 [TBL] [Abstract][Full Text] [Related]
9. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647 [TBL] [Abstract][Full Text] [Related]
10. The effect of off-pump coronary artery bypass grafting on platelet activation in patients on aspirin therapy until surgery day. Suwalski G; Suwalski P; Filipiak KJ; Postuła M; Majstrak F; Opolski G Eur J Cardiothorac Surg; 2008 Aug; 34(2):365-9; discussion 369. PubMed ID: 18550381 [TBL] [Abstract][Full Text] [Related]
11. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Poulsen TS; Mickley H; Korsholm L; Licht PB; Haghfelt T; Jørgensen B Thromb Res; 2007; 120(2):161-72. PubMed ID: 17052745 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317 [TBL] [Abstract][Full Text] [Related]
13. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group. Second Chinese Cardiac Study (CCS-2) Collaborative Group J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251 [TBL] [Abstract][Full Text] [Related]
15. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493 [TBL] [Abstract][Full Text] [Related]
16. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Małek ŁA; Spiewak M; Filipiak KJ; Grabowski M; Szpotańska M; Rosiak M; Główczyńska R; Imiela T; Huczek Z; Opolski G Kardiol Pol; 2007 Jan; 65(1):40-5; discussion 46. PubMed ID: 17295159 [TBL] [Abstract][Full Text] [Related]
17. The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity. Santos MT; Madrid I; Moscardo A; Latorre AM; Bonastre J; Ruano M; Valles J Platelets; 2014; 25(4):268-73. PubMed ID: 23909754 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]